Xilio Therapeutics, Inc. (XLO)
 NASDAQ: XLO · Real-Time Price · USD
 0.8036
 -0.0064 (-0.79%)
  At close: Oct 30, 2025, 4:00 PM EDT
0.8200
 +0.0164 (2.04%)
  Pre-market: Oct 31, 2025, 4:35 AM EDT
Xilio Therapeutics Employees
Xilio Therapeutics had 64 employees as of December 31, 2024. The number of employees decreased by 9 or -12.33% compared to the previous year.
Employees 
 64
Change (1Y) 
 -9
Growth (1Y) 
 -12.33%
Revenue / Employee 
 $234,391
Profits / Employee 
 -$878,469
Market Cap 
41.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 64 | -9 | -12.33% | 
| Dec 31, 2023 | 73 | -16 | -17.98% | 
| Dec 31, 2022 | 89 | 15 | 20.27% | 
| Dec 31, 2021 | 74 | - | - | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
XLO News
- 20 hours ago - Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewsWire
- 27 days ago - Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - GlobeNewsWire
- 5 months ago - Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewsWire